ACIP expands Pfizer’s ABRYSVO vaccine guidance to include at-risk adults aged 50–59
Pfizer's RSV vaccine ABRYSVO now recommended for at-risk adults aged 50–59. Learn what it means for public health and Pfizer’s expanding vaccine portfolio. Read More
Clover Biopharmaceuticals receives FDA clearance for RSV vaccine trial, expands respiratory disease research
Clover Biopharmaceuticals advances RSV vaccine research with FDA-approved SCB-1019 trials, targeting revaccination gaps and combination immunization strategies. Read More
China discovers new bat coronavirus HKU5-CoV-2: How serious is the threat?
A newly identified bat coronavirus, HKU5-CoV-2, has been discovered by Chinese scientists, raising concerns about animal-to-human transmission and its potential public health implications. The virus ... Read More
Pfizer’s ADCETRIS combination regimen secures FDA approval for relapsed large B-cell lymphoma
The U.S. Food and Drug Administration (FDA) has approved Pfizer Inc.’s supplemental Biologics License Application (sBLA) for ADCETRIS (brentuximab vedotin) in combination with lenalidomide and ... Read More
FDA approves EMBLAVEO to combat complicated intra-abdominal infections with limited treatment options
The U.S. Food and Drug Administration (FDA) has granted approval for EMBLAVEO (aztreonam and avibactam), marking a significant milestone in the fight against complicated intra-abdominal ... Read More
Pfizer reports strong Q4 2024 earnings, reaffirms 2025 guidance amid cost-cutting strategy
Pfizer Inc. delivered strong fourth-quarter 2024 earnings, exceeding analyst expectations and demonstrating resilience in a challenging pharmaceutical market. The company reaffirmed its 2025 financial guidance, ... Read More
Pfizer resolves $59.7m kickback allegations linked to Biohaven’s marketing practices
Pharmaceutical giant Pfizer Inc., acting on behalf of its subsidiary Biohaven Pharmaceutical Holding Company Ltd., has agreed to a $59.7 million settlement to resolve allegations ... Read More
Pfizer’s BRAFTOVI regimen doubles response rates for metastatic colorectal cancer
Pfizer Inc. has unveiled compelling findings from the Phase 3 BREAKWATER trial, highlighting the efficacy of its BRAFTOVI (encorafenib) combination regimen in treating metastatic colorectal ... Read More
Zai Lab and Pfizer collaborate to address drug-resistant infections in China
Zai Lab and Pfizer have entered a partnership to commercialize XACDURO (sulbactam-durlobactam) in mainland China, addressing the rising threat of drug-resistant infections caused by carbapenem-resistant ... Read More
Pfizer stuns Wall Street with booming Q3 earnings and new guidance boost
Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising its annual revenue and earnings guidance for ... Read More